Peyrin-Biroulet L - Search Results

1

Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.

D'Haens G, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV Jr, Panés J, Peyrin-Biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, Kligys K, Pang Y, Pivorunas V, Berg S, Duan WR, Huang B, Kalabic J, Liao X, Robinson A, Wallace K, Ferrante M. D'Haens G, et al. Lancet. 2022 May 28;399(10340):2015-2030. doi: 10.1016/S0140-6736(22)00467-6. Lancet. 2022. PMID: 35644154 Clinical Trial.

2

Mesenteric fat in Crohn's disease: a pathogenetic hallmark or an innocent bystander?

Peyrin-Biroulet L, Chamaillard M, Gonzalez F, Beclin E, Decourcelle C, Antunes L, Gay J, Neut C, Colombel JF, Desreumaux P. Peyrin-Biroulet L, et al. Gut. 2007 Apr;56(4):577-83. doi: 10.1136/gut.2005.082925. Epub 2006 Sep 6. Gut. 2007. PMID: 16956921 Free PMC article. Review. No abstract available.

3

Antimycobacterial therapy in Crohn's disease: game over?

Peyrin-Biroulet L, Neut C, Colombel JF. Peyrin-Biroulet L, et al. Gastroenterology. 2007 Jun;132(7):2594-8. doi: 10.1053/j.gastro.2007.04.027. Gastroenterology. 2007. PMID: 17570230 Review. No abstract available.

4

Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials.

Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. Peyrin-Biroulet L, et al. Clin Gastroenterol Hepatol. 2008 Jun;6(6):644-53. doi: 10.1016/j.cgh.2008.03.014. Clin Gastroenterol Hepatol. 2008. PMID: 18550004

5

Early combined immunosuppression in Crohn's disease.

Danese S, Peyrin-Biroulet L. Danese S, et al. Lancet. 2008 Jun 14;371(9629):1996; author reply 1996-7. doi: 10.1016/S0140-6736(08)60862-4. Lancet. 2008. PMID: 18555908 No abstract available.

6

Crohn's disease: beyond antagonists of tumour necrosis factor.

Peyrin-Biroulet L, Desreumaux P, Sandborn WJ, Colombel JF. Peyrin-Biroulet L, et al. Lancet. 2008 Jul 5;372(9632):67-81. doi: 10.1016/S0140-6736(08)60995-2. Lancet. 2008. PMID: 18603161 Review.

7

Effects of infliximab therapy on abdominal fat and metabolic profile in patients with Crohn's disease.

Parmentier-Decrucq E, Duhamel A, Ernst O, Fermont C, Louvet A, Vernier-Massouille G, Cortot A, Colombel JF, Desreumaux P, Peyrin-Biroulet L. Parmentier-Decrucq E, et al. Inflamm Bowel Dis. 2009 Oct;15(10):1476-84. doi: 10.1002/ibd.20931. Inflamm Bowel Dis. 2009. PMID: 19291781

8

Insufficient evidence to conclude whether anti-tumor necrosis factor therapy increases the risk of lymphoma in Crohn's disease.

Peyrin-Biroulet L, Colombel JF, Sandborn WJ. Peyrin-Biroulet L, et al. Clin Gastroenterol Hepatol. 2009 Oct;7(10):1139. doi: 10.1016/j.cgh.2009.05.012. Epub 2009 May 22. Clin Gastroenterol Hepatol. 2009. PMID: 19465159 No abstract available.

9

Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis.

Peyrin-Biroulet L, Deltenre P, Ardizzone S, D'Haens G, Hanauer SB, Herfarth H, Lémann M, Colombel JF. Peyrin-Biroulet L, et al. Am J Gastroenterol. 2009 Aug;104(8):2089-96. doi: 10.1038/ajg.2009.301. Epub 2009 Jun 30. Am J Gastroenterol. 2009. PMID: 19568226 Review.

10

Ulcerative colitis: Natural history--an optimistic message from Norway.

Peyrin-Biroulet L, Colombel JF. Peyrin-Biroulet L, et al. Nat Rev Gastroenterol Hepatol. 2009 Jul;6(7):387-8. doi: 10.1038/nrgastro.2009.100. Nat Rev Gastroenterol Hepatol. 2009. PMID: 19575022 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,100 results

Search Page

Filters